Treatment options in unstable angina: a clinical update
1Department of Cardiology, University of Edinburgh, UK.
Insights
Low-molecular-weight heparin (LMWH) enoxaparin offers a more effective treatment for unstable coronary artery disease than unfractionated heparin. This improved efficacy, particularly with a 1.0 mg/kg dose, persists post-treatment with fewer major hemorrhages.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Unstable coronary artery disease treatment commonly uses aspirin and intravenous heparin.
- This standard treatment has a notable failure rate due to heparin and aspirin's properties.
- Low-molecular-weight heparins (LMWHs) present theoretical and practical advantages over unfractionated heparin.
Purpose of the Study:
- To evaluate the efficacy and safety of enoxaparin, a specific LMWH, compared to unfractionated heparin in treating unstable coronary artery disease.
- To assess the long-term benefits and optimal dosage of enoxaparin.
Main Methods:
- Clinical trials were conducted to compare enoxaparin with unfractionated heparin.
- Enoxaparin was administered subcutaneously at 1.0 mg/kg every 12 hours for 2-8 days.
- Different dosages of enoxaparin were assessed for efficacy and bleeding risk.
Main Results:
- Enoxaparin (1.0 mg/kg every 12h) demonstrated significantly greater effectiveness than unfractionated heparin.
- The therapeutic benefits of enoxaparin extended beyond the treatment period.
- A dosage of 1.0 mg/kg every 12h showed efficacy comparable to higher doses but with a substantially reduced rate of major hemorrhage.
Conclusions:
- Enoxaparin is a more effective treatment option for unstable coronary artery disease compared to unfractionated heparin.
- The 1.0 mg/kg every 12h dosage of enoxaparin provides optimal efficacy with an improved safety profile, specifically lower bleeding risk.
Abstract:
Treatment of unstable coronary artery disease with a combination of aspirin and intravenous heparin is now widely established but carries a significant failure rate, the origins of which lie in the fundamental characteristics of heparin and aspirin. The use of low-molecular-weight heparins (LMWHs) as an alternative to unfractionated heparin carries theoretical and practical advantages. Clinical trial evidence is now available to show that the LMWH enoxaparin, in a dosage of 1.0 mg x kg(-1) subcutaneously every 12 h for 2-8 days, is significantly more effective than unfractionated heparin, and that the benefits persist even after treatment ends. Ongoing trials will provide more efficacy data over both the short and the longer term. Enoxaparin at a dosage of 1.0 mg x kg(-1) every 12 h is as effective as higher doses but is associated with a much lower rate of major haemorrhage.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina II: Classification
Angina III: Clinical Manifestations and Assessment
Angina IV: Management
Angina V: Nursing Management


